rbd4059
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05653037)
Timeline
Indications
Mechanism of action
- Caspase-2ANTISENSE INHIBITOR
CASP2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06717074 | Phase 2 | Aug 28, 2024 | Ribocure Pharmaceuticals AB |
| NCT05653037 | Phase 1 | Feb 28, 2023 | Suzhou Ribo Life Science Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ribocure Pharmaceuticals AB | For profit | 1 | 1 | 1 | 2024 |
| Suzhou Ribo Life Science Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1